A phase 1 study of JNJ-86974680, an A2a receptor antagonist, administered as monotherapy and in combination with cetrelimab and radiotherapy for advanced non-small cell lung cancer
Phase 1
Recruiting
- Conditions
- Advanced non-small cell lung cancerTherapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2023-506393-12-00
- Lead Sponsor
- Johnson And Johnson Enterprise Innovation Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 67
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method